Lv53
1240 积分 2024-02-02 加入
149MO Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study
1个月前
已完结
FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2
1个月前
已完结
Epithelial-Mesenchymal Transition in Metastatic Colorectal Cancer
1个月前
已关闭
Occurrence and prognosis of lung cancer metastasis to major organs: a population-based study
1个月前
已完结
Fibroblast growth factor receptors 1 and 4 combined with lymph node metastasis predicts poor prognosis in oral cancer
1个月前
已完结
Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness
1个月前
已关闭
Next-generation isoform-selective fibroblast growth factor receptor inhibitors
1个月前
已完结
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
1个月前
已完结
Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains
1个月前
已完结
Resistance to Chemotherapy Is Associated with Fibroblast Growth Factor Receptor 4 Up-Regulation
1个月前
已完结
皖公网安备34019202002308
